The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections
about
Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applicationsRisks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisGlatiramer acetate for treatment of MS: regulatory B cells join the cast of players.Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: a paradigm shift.Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cellsImmune modulating peptides for the treatment and suppression of multiple sclerosis.Glatiramer acetate in multiple sclerosis.Interferon beta and glatiramer acetate therapy.Glatiramer acetate attenuates the activation of CD4+ T cells by modulating STAT1 and -3 signaling in glia.Translational research in neurology and neuroscience 2010: multiple sclerosisA Comprehensive Review on Copemyl(®).Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.Process signatures in glatiramer acetate synthesis: structural and functional relationships.Probing into the realm of proteins and immunity.Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.From academic laboratory to the market: Disclosed and undisclosed narratives of commercialization.The heritage of glatiramer acetate and its use in multiple sclerosis
P2860
Q28282507-1F0C305F-A671-4CE5-8915-BEA929EA0818Q33802186-3A62786A-22C4-47BB-813D-08DAF6E74A5DQ34479298-71E2D13E-2856-49A1-8A09-7967381C3FFEQ34956279-6A63E5EE-2FB6-4EBA-8D2D-0E244BADCA04Q35160777-BF7CC7EB-4E01-481F-BE9E-D8743B4C04DFQ36151968-8D553667-61B0-4B4E-85BA-3F1BEE71DF12Q36198583-58258992-8605-461C-A199-3FDB246352C4Q36568660-AB04CF32-642F-403B-BC0B-D492591CE0DEQ37589284-5AB9ACE1-0ADC-4977-94BF-EA3902531DC0Q37772026-55555A07-073E-4C9E-8C0E-B8326478C126Q38650000-25B83B4C-306D-4FDC-AC1A-F668AE8A8A7BQ39672574-8E3A80C0-4419-45AC-A567-500FE7C3051AQ42362266-E3243C86-42C3-4E3D-AF85-F43BB14C32BDQ42846579-9CD7F784-B44E-4A50-B87C-A683A3A021EBQ44685789-38389AF2-045D-4A9C-86DA-A1098A8188DCQ47234759-93DDA74E-163B-4416-B36F-8630BD1E330CQ56804781-F2BC20BC-C5CD-47F1-8586-EB1B881AC777
P2860
The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections
description
1996 nî lūn-bûn
@nan
1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
The development of Cop 1 (Copa ...... clerosis: personal reflections
@ast
The development of Cop 1 (Copa ...... clerosis: personal reflections
@en
The development of Cop 1 (Copa ...... clerosis: personal reflections
@nl
type
label
The development of Cop 1 (Copa ...... clerosis: personal reflections
@ast
The development of Cop 1 (Copa ...... clerosis: personal reflections
@en
The development of Cop 1 (Copa ...... clerosis: personal reflections
@nl
prefLabel
The development of Cop 1 (Copa ...... clerosis: personal reflections
@ast
The development of Cop 1 (Copa ...... clerosis: personal reflections
@en
The development of Cop 1 (Copa ...... clerosis: personal reflections
@nl
P1433
P1476
The development of Cop 1 (Copa ...... clerosis: personal reflections
@en
P2093
P356
10.1016/0165-2478(96)02506-0
P407
P577
1996-04-01T00:00:00Z